"Deferoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
| Descriptor ID |
D003676
|
| MeSH Number(s) |
D02.092.570.394.265 D02.241.511.372.265
|
| Concept/Terms |
Deferoxamine- Deferoxamine
- Desferrioxamine
- Desferioximine
- Deferoxamine B
- Desferrioxamine B
- Deferoximine
- Deferrioxamine B
- Desferroxamine
Desferrioxamine B Mesylate- Desferrioxamine B Mesylate
- Mesylate, Desferrioxamine B
- Deferoxamine Mesilate
- Mesilate, Deferoxamine
- Deferoxamine Mesylate
- Mesylate, Deferoxamine
- Deferoxamine Methanesulfonate
- Methanesulfonate, Deferoxamine
|
Below are MeSH descriptors whose meaning is more general than "Deferoxamine".
Below are MeSH descriptors whose meaning is more specific than "Deferoxamine".
This graph shows the total number of publications written about "Deferoxamine" by people in this website by year, and whether "Deferoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deferoxamine" by people in Profiles.
-
Deferoxamine prevents poststroke memory impairment in female diabetic rats: potential links to hemorrhagic transformation and ferroptosis. Am J Physiol Heart Circ Physiol. 2023 02 01; 324(2):H212-H225.
-
The role of Iron in lipid peroxidation and protein nitration during acetaminophen-induced liver injury in mice. Toxicol Appl Pharmacol. 2022 06 15; 445:116043.
-
Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 07; 53(7):2204-2210.
-
Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial. Stroke. 2022 04; 53(4):1149-1156.
-
Why Are Women Less Represented in Intracerebral Hemorrhage Trials? Stroke. 2021 01; 52(2):442-446.
-
Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. Transl Stroke Res. 2021 08; 12(4):615-630.
-
Pervasive Genomic Damage in Experimental Intracerebral Hemorrhage: Therapeutic Potential of a Mechanistic-Based Carbon Nanoparticle. ACS Nano. 2020 03 24; 14(3):2827-2846.
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
-
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity. J Pharmacol Sci. 2017 Aug; 134(4):203-210.
-
Effect of Natural Organic Matter on Plutonium Sorption to Goethite. Environ Sci Technol. 2017 01 03; 51(1):699-708.